솔리드 바이오사이언시스(SLDB)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $8.91 (+0.45%), 시가총액 $0.76B, 52주 최저~최고 $2.55 ~ $8.63.
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations
솔리드 바이오사이언시스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
솔리드 바이오사이언시스의 현재 주가는 $8.91 (+0.45%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
솔리드 바이오사이언시스의 시가총액은 약 $0.76B입니다.
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duche